RxDoctor Payments Data

Michael Taylor, MD

Ophthalmology · Twin Falls, IDNPI 1851338925

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Astellas Pharma US Inc at 42.5% of the total. Reporting peaked in 2024 at $152 and has fallen 81.4% since, to $28 in 2025. That places this record below the midpoint for ophthalmology clinicians in ID, where the typical reported total is $971.

$358in general payments, 2019–2025

Across 10 payments — averaging $35.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$152
  • Biotissue Holdings Inc.$65
  • Rxsight Inc$50
  • Alcon$49
  • AbbVie$28
  • Regeneron Healthcare Solutions, Inc.$13

What the payments were for

  • Food & beverage$358100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$358 in reported general payments places this provider in the 20th percentile of 60 ophthalmology providers in Idaho.

See all ophthalmology providers in Idaho

Medicare billing

Part B allowed, 2024
$1,395,910
Medicare patients
762
Services billed
16,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost97$44,119
RestasisCyclosporine28$17,854
Alphagan PBrimonidine Tartrate16$7,269
SimbrinzaBrinzolamide/Brimonidine Tart21$4,246
Cyclosporine12$3,784
Latanoprost361$3,628
Prednisolone Acetate78$3,242
Brinzolamide14$2,511
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$2,469
Tobramycin-DexamethasoneTobramycin/Dexamethasone45$1,784
Timolol Maleate97$1,455
Ketorolac Tromethamine52$1,396
Doxycycline Monohydrate11$1,049
Brimonidine Tartrate108$860
Ofloxacin52$630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P$28$69,243141 claims
AlconSimbrinza$49$4,24621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 60 ophthalmology providers in Idaho.

Other ophthalmology in Twin Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →